SUMMARY Thirty two patients with ankylosing spondylitis were investigated with a set of pulmonary function tests and the results compared with those for a control population. The patients had no complaints about lung symptoms and their chest radiographs were normal. The main pathological findings were reduced lung volumes, a raised closing volume/vital capacity ratio, and a decreased volumic airway conductance. The lung volume reduction correlated with disease duration, thoracic mobility, and degree of acute phase reaction. The stiff spondylitic thorax probably makes the main contribution to the impairment of lung function in these patients, but the findings in this study also suggest an involvement of the small airways. This type of pulmonary function testing seems valuable even in patients with ankylosing spondylitis without lung symptoms and it might be used as a tool in the staging of the disease, to evaluate treatment and to differentiate from fibrosis.
Thirty two outpatients with definite AS according to American Rheumatism Association criteria (New York) were recruited consecutively for this study. No selection was made because of lung symptoms or x ray findings. The clinical and laboratory features of five AS patients are shown in Table 1 .
The following spirometric tests were performed: measurements of the total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV), together with airways resistance (Raw) and volumic airways conductance (Gaw/V) using a body plethysmograph; ventilatory capacity, including flow-volume curves for determination of vital capacity (VC), forced expiratory volume in one second (FEV1), FEV1 as percentage of VC (FEV1/ VC), maximal voluntary ventilation at breathing rate of 40 breaths/min (MVV40), peak expiratory flow rate (PEF), and maximal expiratory flows at 75%, 50%, and 25% of the forced vital capacity (MEF75, MEF50, and MEF25); single-breath nitrogen wash out test for measurement of the intrapulmonary gas distribution (phase III), closing volume (CV), and CV as percentage of VC (CV/VC); transfer factor (TLCO) or diffusing capacity for carbon monoxide (single-breath test) and measure- Erythrocyte sedimentation rate (ESR) was read after one hour. Serum levels (reference ranges are given in parentheses) of haptoglobin (0-3-2-0 g/l), orosomucoid (0-4-1-2 g/l, and IgA (0.8-4-0 gIl) were measured by nephelometry at the Department of Clinical Chemistry, University Hospital, Uppsala.
CALCULATIONS AND STATISTICS
The lung function values were expressed as residuals (observed value-predicted value) and as a percentage of predicted values using regression equations which take into account the effect of sex, age, body size, and smoking habits. 4 5 In the statistical analysis the t distribution was used to determine the significance level between the AS group and the normal reference group: 456 healthy subjects (270 men, 186 women) with normal chest radiographs. Half of the healthy subjects had never been smokers and half were smokers. The Pearson correlation coefficient was used to measure the correlation between pulmonary function variables and inflammatory activity variables. Discriminant analysis was used to detect optimal variables for discrimination between the AS group and normal subjects and between the AS group and patients with pulmonary fibrosis (38 patients with pleura plaques, 40 patients with silicosis on the basis of chest radiographs, and 33 stone crushers exposed to silicon dust but with normal chest radiographs).6 7
Results

LUNG FUNCTION AND LUNG VOLUMES
Variables reflecting lung volumes and functions are Pulmonary involvement in ankylosing spondylitis 737 the number of SD from predicted values. The optimal discriminating profile was: -0-07xVC +004xCst-0-02xGaw/V-OO1xCV/VC. The sensitivity obtained was 55% and the specificity against healthy controls 84% and against patients with lung fibrosis 75%. The correlative studies are summarised in Table 3 and graphically illustrated in Haptoglobin g/l Fig. 1 Correlation between vital capacity, expressed as number ofstandard deviations (SD), and thoracic expansion, disease duration, and haptoglobin. Thoracic expansion v haptoglobin is also illustrated. niques was significantly related to the disease duration, thoracic mobility, and inflammatory activity defined by ESR, haptoglobin, orosomucoid, and IgA. The strongest correlations were observed between lung volumes and thoracic mobility (Table 3 , Fig. 1 ). The thoracic mobility was also related to ESR (r=-0.47, p<0-01), haptoglobin (r=-0.42, p<0-05), and orosomucoid (r=-0-56, p<0-001). The minor abnormalities of the airway resistance did not correlate with these clinical and laboratory variables. Although the CV values did not differ from those of the controls we observed a negative relationship between CV and disease duration (r=-0*38, p<0.05) and a positive relationship with thoracic mobility (r=0*38, p<005). The CVIVC ratio tended to correlate with these clinical variables (r= -0.32, p<0.05 and r=0*23, p=0i1 respectively).
CV and CV/VC did not correlate with the inflammatory activity.
All patients except one had normal chest x rays. The exception had bilateral upper lobe changes with infiltrates radiating from the hili.
Discussion
This study has shown that randomly selected patients with AS without symptoms of lung disease suffer from reduced lung volumes as defined by reduced vital capacity and reduced total lung capacity. Normal functional residual capacity and normal residual volume suggest a restrictive limitation of the lung volumes, further supported by the normal flow values. The reason for this lung function impairment could be an altered lung parenchyma with tendency to fibrosis or a reduced mobility of the thoracic cage due to inflammation or ankylosis of sternocostal and costovertebral joints and adjacent synchondroses. Since disease duration also was related to the reduction of lung volumes this suggests a process developing with time, finally resulting in a permanently reduced lung capacity. The observation that the reduced lung volumes were also related to inflammatory intensity of the disease may suggest an inflammatory involvement of the lung parenchyma. The acute phase reaction, however, was more strongly correlated with the thoracic mobility, which gives a more likely explanation of this relationship, namely that ongoing inflammatory processes in the thoracic joints give rise to pain and stiffness thus reducing the lung volumes. The concept that the inflammatory activity in the thoracic cage or in the lung parenchyma fluctuates in parallel with the activity of the rheumatic disease can only be decided by longitudinal studies. 
